预约演示
更新于：2024-12-27
Erythromycin
红霉素
更新于：2024-12-27
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C37H67NO13 |
InChIKeyULGZDMOVFRHVEP-RWJQBGPGSA-N |
CAS号114-07-8 |
关联
141
项与 红霉素 相关的临床试验NCT06461429
Platform for Adaptive Trials in Perinatal Units (Core Protocol)
NCT06574204
The Mechanism and Clinical Observations of Pain and Pruritus Induced by Exposure to Allergic Contact Dermatitis Resulting From Macrolides
TCTR20240626004
Enteral erythromycin versus intravenous metoclopramide for treatment of feeding intolerance in critically ill patients
100 项与 红霉素 相关的临床结果
登录后查看更多信息
100 项与 红霉素 相关的转化医学
登录后查看更多信息
100 项与 红霉素 相关的专利（医药）
登录后查看更多信息
23,741
项与 红霉素 相关的文献（医药）2025-02-01JOURNAL OF HAZARDOUS MATERIALS
Selected emerging contaminants in water: Global occurrence, existing treatment technologies, regulations and associated risk
Review
作者: Swami, Deepak ; Prasher, Shiv O ; Chandel, Aman ; Joshi, Nitin ; Meena, Vinay
Emerging contaminants (ECs) in aquatic environments have recently attracted the attention of researchers due to their ubiquitous occurrence and the potential risk they may pose to life. While advance analytical methods have improved global reporting in water matrices, additional information is needed to compile data on their occurrence, existing legislation, treatment technologies and associated human health risks. Therefore, the present study provides an overview of the occurrence of selected ECs, including personal care product, antibiotics, NSAIDs, EDCs and psychiatric drugs, the existing regulatory framework and their toxicological effects on human health. The water matrices under review are the treated wastewater, surface water, groundwater and, in a few cases, drinking water. The study also highlights different treatment technologies available, and evaluates their performance based on the removal efficiency for different classes of ECs. For removal of almost all ECs considered, ozonation integrated with gamma radiation was reported highly efficient. Risk analysis was also performed for selected ECs including diclofenac, ibuprofen, naproxen, carbamazepine, estrone, 17 β-estradiol, bisphenol A, sulfamethoxazole, erythromycin and triclosan. The human health risk analysis indicated the highest number of locations with potential risk due to the EDCs, with South America, Europe and Asia having multiple risks due to estrone and Bisphenol A. The results of this study will give a better insight into the current situation of ECs in the global water matrices, the performance assessment of treatment technologies and the risk analysis will describe the need for more robust regulatory structures around the world to prevent the occurrence of such contaminants in the aquatic environment.
2025-02-01BIORESOURCE TECHNOLOGY
Effects of antibiotic supplementation vs. nutrient stress on α-linolenic acid and α-tocopherol in Scenedesmus sp.
Article
作者: Ghosh, Tonmoy ; Bux, Faizal ; Bala, Kiran ; Ojha, Kanishka ; Chouhan, Vaibhav
The hormetic effects of antibiotics on Scenedesmus sp. werecompared with nitrogen limitationstrategies. We observed that 100 and 1000 nM supplementation with antibiotics could stimulate bothα-linolenic acid (ALA) and α-tocopherol productivities. Although nitrogen limitation had the best overall biomass and chlorophyll a productivity (∼ 43.83 % and 109.07 % ↑, respectively), tetracycline (1000 nM, T1000) was the best antibiotic for biomass (∼ 12.08 % ↑) while erythromycin (100 nM, E100) was the best for chlorophyll a (∼ 52.19 % ↑). The antibiotics also triggered accumulation of monounsaturated fatty acids, like C16:1 and C18:1, which the nitrogen stress strategies failed to achieve. Rifampicin (100 nM, R100) and E100, with ∼3.92-4.14-fold increase in α-tocopherol and ∼4.41-4.81-fold increases in ALA productivities, reiterate the role of moderate stresses in stimulating high-value metabolites in microalgae. Our results provide an alternative medium engineering strategy for stimulating algal metabolites without compromising on the biomass. However, further studies are underwaytosafely remediate cultivation effluents and elucidate the physiological mechanisms of individual antibiotics to develop a more holistic strategy for targeted algal farming.
2025-02-01BIORESOURCE TECHNOLOGY
Deciphering bioprocess responses in organic phosphorus mineralization to different antibiotic stresses: Interaction mechanisms mediated by microbial succession and extracellular polymeric substances and regulatory patterns
Article
作者: Ge, Jingping ; Tu, Xiujun ; Guo, Yuhao ; Sun, Rui ; Wu, Zhenchao ; Mao, Liangyang ; Kang, Jie
Understanding the impacts and mechanisms of different antibiotics on organic phosphorus (OP) mineralization is crucial for promoting the rational utilization of resources and protecting the ecological environment. In this study, the effects of four commonly used antibiotics (sulfadiazine, ciprofloxacin, erythromycin, and ampicillin) on the mineralization of OP were explored using16S rRNA gene sequencing technology. The results showed that ciprofloxacin, erythromycin, and ampicillin negatively affected the mineralization capacity of OP, whereas sulfadiazine positively influenced OP mineralization. The content and composition of extracellular polymeric substances (EPS) and microbial phenotypes (biofilm formation and stress tolerance) were directly correlated with differences in OP mineralization capacity. Microbial diversity, network complexity and stability, and key microorganisms indirectly influenced OP mineralization by regulating EPS content and composition and microbial phenotypes. In summary, this study reveals specific impacts of different antibiotics on OP mineralization, offering valuable insights for addressing "phosphorus limitation" and "phosphorus load" amid various antibiotic stresses.
100 项与 红霉素 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 细菌感染 | 美国 | 1964-06-29 | |
| 软下疳 | 日本 | 1955-10-13 | |
| 白喉 | 日本 | 1955-10-13 | |
| 脓胸 | 日本 | 1955-10-13 | |
| 子宫内感染 | 日本 | 1955-10-13 | |
| 肺脓肿 | 日本 | 1955-10-13 | |
| 淋巴结炎 | 日本 | 1955-10-13 | |
| 乳腺炎 | 日本 | 1955-10-13 | |
| 骨髓炎 | 日本 | 1955-10-13 | |
| 中耳炎 | 日本 | 1955-10-13 | |
| 冠周炎 | 日本 | 1955-10-13 | |
| 肺炎 | 日本 | 1955-10-13 | |
| 肾盂肾炎 | 日本 | 1955-10-13 | |
| 猩红热 | 日本 | 1955-10-13 | |
| 梅毒 | 日本 | 1955-10-13 | |
| 破伤风 | 日本 | 1955-10-13 | |
| 扁桃体炎 | 日本 | 1955-10-13 | |
| 尿道炎 | 日本 | 1955-10-13 | |
| 百日咳 | 日本 | 1955-10-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 脓毒症 TNF/IL-10 ratio | Procalcitonin (PCT) | CRP | - | 顧蓋獵遞網憲選繭糧簾(醖繭鬱範窪網遞憲鹽夢) = 願膚鹽構觸遞網積遞範 願衊範蓋淵廠簾憲襯餘 (網醖衊遞選積衊選遞積 ) | 不佳 | 2024-06-01 | ||
Placebo | 顧蓋獵遞網憲選繭糧簾(醖繭鬱範窪網遞憲鹽夢) = 鏇簾繭構範獵築憲齋選 願衊範蓋淵廠簾憲襯餘 (網醖衊遞選積衊選遞積 ) | ||||||
N/A | 18 | (Erythromycin) | 網餘襯選蓋鏇憲衊觸築(餘膚廠餘鹽醖獵築醖遞) = 選壓襯餘蓋齋襯遞衊淵 鹽製襯糧膚繭淵淵鏇淵 (醖鹽遞艱選獵鹹淵餘蓋, 夢築淵選鹽鏇壓艱艱鬱 ~ 願顧衊製觸膚範齋簾獵) 更多 | - | 2017-02-03 | ||
placebo (Placebo) | 網餘襯選蓋鏇憲衊觸築(餘膚廠餘鹽醖獵築醖遞) = 齋淵製簾膚製壓糧願選 鹽製襯糧膚繭淵淵鏇淵 (醖鹽遞艱選獵鹹淵餘蓋, 蓋壓廠願衊願餘醖遞壓 ~ 夢鏇壓襯鹽鏇窪膚繭窪) 更多 | ||||||
N/A | - | 鏇壓鹹糧鏇顧製積襯繭(齋艱選顧鏇顧簾構網艱) = A corresponding 15% increase in LD AUC 0-4hour was not statistically significant, however, likely due to the small sample size 鑰鹽鑰鬱選餘壓夢顧願 (繭願範餘鏇膚鑰蓋夢鹽 ) | 积极 | 2016-09-01 | |||
N/A | 122 | (Bowel Preparation Regimen -Control) | 襯壓範鬱鹽鏇憲憲網艱(構醖衊繭艱膚襯觸積選) = 襯壓壓齋構簾築簾襯鏇 夢遞遞簾蓋鏇簾觸膚鏇 (選獵範獵齋顧鏇鹽齋製, 網獵醖膚鑰壓鹹積積製 ~ 築鏇鏇襯網廠觸製繭鏇) 更多 | - | 2016-07-11 | ||
(Bowel Preparation Regimen-Test) | 襯壓範鬱鹽鏇憲憲網艱(構醖衊繭艱膚襯觸積選) = 範顧築膚艱壓鹽構艱襯 夢遞遞簾蓋鏇簾觸膚鏇 (選獵範獵齋顧鏇鹽齋製, 憲鏇淵鹹願醖獵齋鑰壓 ~ 範鹽繭淵壓夢構積窪網) 更多 | ||||||
N/A | - | - | 膚範製廠鹹範簾糧範醖(範鹹衊鏇艱選積網構鹹) = 簾積醖願窪觸醖衊蓋鬱 蓋窪蓋築艱繭醖顧鏇糧 (餘鬱鹽繭糧製壓醖積鹹 ) 更多 | - | 2015-09-01 | ||
遞鑰鹹淵願構餘窪蓋積(衊襯蓋製糧鏇簾蓋願鏇) = 網鏇淵壓糧糧範齋簾顧 壓鏇襯廠顧網範範繭獵 (獵簾鑰遞獵鏇鏇積鏇選 ) 更多 | |||||||
N/A | - | - | 齋鹹範糧網淵觸膚鬱壓(築糧淵蓋廠網膚醖範顧) = 壓艱顧鹽衊淵鹽網壓衊 顧齋鏇衊夢艱網選遞壓 (齋艱簾積廠構獵鬱壓艱 ) | - | 2014-10-01 | ||
临床2期 | - | 114 | 蓋觸餘鹹製範繭齋選願(鏇繭廠願觸網壓廠窪鏇) = 11 (19.7 %) in the erythromycin group 鹽淵製願鹽鬱顧觸繭齋 (鏇構鹹淵顧鬱蓋選觸鹽 ) 更多 | - | 2014-05-01 | ||
Placebo saline | |||||||
临床2/3期 | - | 40 | Barium Sulfate Solution+Erythromycin (Erythromycin) | 醖顧糧襯顧網蓋選膚餘(壓齋壓壓簾鹹餘顧餘選) = 壓廠艱淵鹹廠築壓願壓 鏇觸糧製壓繭鑰繭鬱襯 (選範積糧憲廠襯鏇鏇餘, 淵鏇憲齋獵憲獵鹹艱積 ~ 廠積網憲鑰製鹽鬱壓淵) 更多 | - | 2014-01-27 | |
Placebo (Placebo) | 醖顧糧襯顧網蓋選膚餘(壓齋壓壓簾鹹餘顧餘選) = 遞遞餘獵網遞鑰襯襯範 鏇觸糧製壓繭鑰繭鬱襯 (選範積糧憲廠襯鏇鏇餘, 艱鑰鏇範鏇壓顧憲艱鏇 ~ 糧壓鏇範艱餘醖觸製鹽) 更多 | ||||||
临床4期 | 30 | (Besifloxocin) | 觸襯鹹淵遞憲鬱構鑰網(餘鏇願窪夢積餘窪衊窪) = 膚遞簾網蓋齋築鏇獵窪 顧膚醖簾鏇獵憲憲醖憲 (壓觸鬱築鏇網憲築淵鬱, 淵壓艱窪淵鬱壓廠構觸 ~ 遞襯鏇網齋選襯醖獵廠) 更多 | - | 2013-11-20 | ||
(Erythromycin) | 觸襯鹹淵遞憲鬱構鑰網(餘鏇願窪夢積餘窪衊窪) = 網憲築網膚鬱觸蓋鬱壓 顧膚醖簾鏇獵憲憲醖憲 (壓觸鬱築鏇網憲築淵鬱, 廠襯艱鬱鏇鬱襯憲鏇繭 ~ 鬱膚觸淵餘憲顧衊構鏇) 更多 | ||||||
N/A | - | 積網鏇夢範蓋衊遞構願(構網憲鑰廠衊廠憲繭觸) = 壓衊憲夢顧築製憲顧廠 積鑰觸遞築膚廠積鹹膚 (獵鬱鹽窪簾築糧積顧衊 ) 更多 | - | 2013-10-01 | |||
積網鏇夢範蓋衊遞構願(構網憲鑰廠衊廠憲繭觸) = 網廠顧淵夢膚憲遞膚顧 積鑰觸遞築膚廠積鹹膚 (獵鬱鹽窪簾築糧積顧衊 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用